FMTX News and Press, Forma Therapeutics Holdings Inc. From 10/26/20

Forma Therapeutics Holdings (FMTX) announces positive preliminary data from a planned interim analysis of a Phase 2 clinical trial evaluating olutasidenib (FT-2102) in patients with isocitrate dehydrogenase 1 ((IDH1)) mutation-positive acute myeloid leukemia ((AML)).Patients receivi...

FT2102-HEM-101 clinical trial data demonstrate a 30% CR and 3% CRh rate with olutasidenib monotherapy in 123 relapsed or refractory IDH1m AML patients While median duration of CR/CRh has not been reached, sensitivity analysis indicates the median duration of CR/CRh to be 13.8 ...

Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointments of Fitzroy Dawkins, M.D., as vice president, clinical development and Ruth du Moulin, Ph.D., as vice president, med...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of industry veteran Thomas G. Wiggans to its board of directors. Mr. Wiggans has led successful biopharmaceutical co...

Forma Therapeutics (NASDAQ: FMTX ) : Q2 GAAP EPS of -$4.58 misses by $3.84 . Cash, cash equivalents and marketable securities were $414.3M. Press Release More news on: Forma Therapeutics Holdings, Inc., Earnings news and commentary, Healthcare stocks news,

Completed upsized IPO in June 2020 raising $319.3 million in gross proceeds Advanced pipeline focused on rare hematologic diseases and cancers, including reporting favorable single-dose data for FT-4202 in sickle cell disease (SCD) from a randomized, multi-center, placebo-controlled Ph...